Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554674 | 1.00 | AVPR1B (0.51) | AVPR1BMAPK14 | |
| SCHEMBL3134898 | 0.80 | AVPR1B (0.76) | AVPR1B | |
| SCHEMBL3134889 | 0.80 | AVPR1B (0.76) | AVPR1B | |
| SCHEMBL3554670 | 0.79 | AVPR1B (0.56) | AVPR1B | |
| SCHEMBL3553545 | 0.77 | MAPT (0.46) | AVPR1B | |
| SCHEMBL3130341 | 0.74 | AVPR1B (0.69) | AVPR1B | |
| SCHEMBL3130335 | 0.74 | AVPR1B (0.69) | AVPR1B | |
| SCHEMBL27712501 | 0.74 | AVPR1B (0.59) | AVPR1B | |
| SCHEMBL27712471 | 0.74 | AVPR1B (0.54) | AVPR1B | |
| SCHEMBL3125112 | 0.69 | AVPR1B (0.88) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | AVPR1B 3/4885MAPK14 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.